CTSO
Cytosorbents Corporation
NasdaqCM Healthcare United States
3,97 $US
-2.10% today
-69.78% YTD · -78.91% 1Y
7
Insider transactions
SEC Form 4 · AMF · BaFin — rolling 90 days
6
Hedge funds tracked
Latest available SEC 13F filings
41
/ 100
MIXED

Analysis Cytosorbents Corporation (CTSO) — Kairos Score 41/100

Composite score aggregating 8 smart money dimensions: insiders (SEC/AMF/BaFin), hedge funds, politicians & gurus, price momentum, valuation, analyst consensus, financial health, earnings momentum. The higher the score, the more favorable the institutional signals consensus.

💡 Detailed breakdown (the 8 sub-scores) available in the Premium dashboard.

About Cytosorbents Corporation

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Key info

👔
CEO
Dr. Phillip P. Chan M.D., Ph.D.
📍
HQ
305 College Road East, Princeton, NJ, 08540, United States
👥
Employees
129
💰
Market cap
12 761 960,00 $US
💸
Dividend yield
—

🕴️ Insider activity (90 days)

7 transactions — 7 buys and 0 sales reported by Cytosorbents Corporation executives.

CP
Chan Phillip P.
Chief Executive Officer · 2026-09-15
Buy
SA
Sobel Alan D.
2026-09-15
Buy
SA
Sobel Alan D.
2026-09-15
Buy

🏦 Hedge Funds

6 institutional funds report a position on CTSO in their latest SEC quarterly filing.

VANGUARD GROUP INC
VANGUARD CAPITAL MANAGEMENT LLC
TIAA CREF INVESTMENT MANAGEMENT LLC
BlackRock, Inc.
GEODE CAPITAL MANAGEMENT, LLC

📰 Recent news

15 recent articles on CTSO.

🧠 What makes Kairos Insider

Beyond raw data, we aggregate and score every smart money signal to give you a unique view.

🧠

Kairos Score 0-100

8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.

🎯

Insider Clusters

Detection of clustered purchases or sales by several executives in the same stock.

🏦

13F Hedge Funds

Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.

📈

ETF Rotations

NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.

🔥

Google Trends

Spot marked changes in search interest around the stocks being followed.

📧

Email alerts

Create your watchlist and receive a brief of events affecting your tickers.

Companies in the same sector as Cytosorbents Corporation

Official sources · Public data · SEC EDGAR — Form 4 & 13F · AMF — Executive filings · BaFin — Directors' Dealings · Yahoo Finance · Alpha Vantage

🔓 Unlock the full analysis

This public page only shows a preview. The full analysis of CTSO on the Kairos Insider dashboard includes:

✅ Full Kairos Score (8-axis radar + synthesis)
✅ History of all 7 insider transactions over 90 days
✅ All 6 detected institutional funds
✅ Thematic ETFs (ARK, BUZZ, NANC, GOP, JEPI…)
✅ Hot Stocks Google Trends
✅ Available history: AUM + rotations
✅ Fundamentals (P/E, PEG, EV/EBITDA, ROE…)
✅ Financial health (Altman Z, Piotroski F)
✅ Sector peers + recent earnings
See full analysis →
Analyze other tickers for free →

Free signup · Pro €19/month or €190/year